A new study published in Nature Metabolism has found that glucosamine is associated with a significantly faster progression from mild cognitive impairment (MCI) to Alzheimer's disease.
The ingredient is one of the most widely used dietary supplements globally, with the findings carrying substantial implications for nutraceutical manufacturers, brands and formulators operating in the joint health space.
The study
The University of Florida research found that glucosamine use is associated with a 25% higher likelihood that a person with MCI will progress to full Alzheimer's disease.
Among patients already diagnosed with Alzheimer's disease and related dementias, glucosamine use was also associated with a 25% increase in mortality risk — though, this elevated risk was not observed in those at the MCI stage, suggesting the supplement's effects may vary depending on disease progression.
The study's scope was extensive, with researchers analysing clinical records identifying more than 50,000 patients diagnosed with Alzheimer's disease-related dementias.
They then used physician notes and prescription records to identify patients with documented glucosamine use of at least one year following diagnosis.
The study identifies hyperglycosylation (an overactive protein sugar-tagging metabolic pathway) as a potential driver of Alzheimer's disease and a promising therapeutic target.
Glucosamine, as a sugar-related molecule, appears to feed directly into this dysfunctional pathway in susceptible brains.
Researchers noted that glucosamine can cross the blood-brain barrier, where it can contribute to biochemical pathways involved in building complex sugar structures on proteins.
In a brain already exhibiting Alzheimer's-related metabolic disruption, supplemental glucosamine could amplify the damage.
"Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles," said senior author Dr Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute.
Mouse model experiments have also supported this hypothesis: animals receiving glucosamine showed worsening social memory deficits, which improved when the sugar-tagging process was chemically suppressed.
However, the researchers were clear that causality has not been established and that clinical trials will be needed.
Industry context
The commercial stakes are significant. The global glucosamine supplements market was valued at approximately $3.8bn in 2025 and is projected to reach $6.2bn by 2033.
Joint health is one of the most established and consumer-trusted categories in nutraceuticals.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.